📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy. (2024)

First Author: Caldwell N

Attributed to: MICA: Development of new agents for the treatment of cryptosporidiosis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.adm8631

PubMed Identifier: 39441903

Publication URI: http://europepmc.org/abstract/MED/39441903

Type: Journal Article/Review

Volume: 16

Parent Publication: Science translational medicine

Issue: 770

ISSN: 1946-6234